173 related articles for article (PubMed ID: 35811524)
1. Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden.
Ramanan VK; Heckman MG; Przybelski SA; Lesnick TG; Lowe VJ; Graff-Radford J; Mielke M; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P;
J Alzheimers Dis; 2022; 88(4):1615-1625. PubMed ID: 35811524
[TBL] [Abstract][Full Text] [Related]
2. Association of
Xicota L; Gyorgy B; Grenier-Boley B; Lecoeur A; Fontaine G; Danjou F; Gonzalez JS; Colliot O; Amouyel P; Martin G; Levy M; Villain N; Habert MO; Dubois B; Lambert JC; Potier MC;
Neurology; 2022 Aug; 99(5):e462-e475. PubMed ID: 35606148
[TBL] [Abstract][Full Text] [Related]
3. Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease.
Ali M; Archer DB; Gorijala P; Western D; Timsina J; Fernández MV; Wang TC; Satizabal CL; Yang Q; Beiser AS; Wang R; Chen G; Gordon B; Benzinger TLS; Xiong C; Morris JC; Bateman RJ; Karch CM; McDade E; Goate A; Seshadri S; Mayeux RP; Sperling RA; Buckley RF; Johnson KA; Won HH; Jung SH; Kim HR; Seo SW; Kim HJ; Mormino E; Laws SM; Fan KH; Kamboh MI; Vemuri P; Ramanan VK; Yang HS; Wenzel A; Rajula HSR; Mishra A; Dufouil C; Debette S; Lopez OL; DeKosky ST; Tao F; Nagle MW; ; ; ; ; ; Hohman TJ; Sung YJ; Dumitrescu L; Cruchaga C
Acta Neuropathol Commun; 2023 Apr; 11(1):68. PubMed ID: 37101235
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
[TBL] [Abstract][Full Text] [Related]
5. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
[TBL] [Abstract][Full Text] [Related]
6. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
7. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.
Nho K; Kim S; Horgusluoglu E; Risacher SL; Shen L; Kim D; Lee S; Foroud T; Shaw LM; Trojanowski JQ; Aisen PS; Petersen RC; Jack CR; Weiner MW; Green RC; Toga AW; Saykin AJ;
BMC Med Genomics; 2017 May; 10(Suppl 1):29. PubMed ID: 28589856
[TBL] [Abstract][Full Text] [Related]
8. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
9. Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.
Ramanan VK; Heckman MG; Lesnick TG; Przybelski SA; Cahn EJ; Kosel ML; Murray ME; Mielke MM; Botha H; Graff-Radford J; Jones DT; Lowe VJ; Machulda MM; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P
Acta Neuropathol; 2022 May; 143(5):571-583. PubMed ID: 35412102
[TBL] [Abstract][Full Text] [Related]
10. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.
Thambisetty M; An Y; Nalls M; Sojkova J; Swaminathan S; Zhou Y; Singleton AB; Wong DF; Ferrucci L; Saykin AJ; Resnick SM;
Biol Psychiatry; 2013 Mar; 73(5):422-8. PubMed ID: 23022416
[TBL] [Abstract][Full Text] [Related]
11. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study.
Ramanan VK; Risacher SL; Nho K; Kim S; Swaminathan S; Shen L; Foroud TM; Hakonarson H; Huentelman MJ; Aisen PS; Petersen RC; Green RC; Jack CR; Koeppe RA; Jagust WJ; Weiner MW; Saykin AJ;
Mol Psychiatry; 2014 Mar; 19(3):351-7. PubMed ID: 23419831
[TBL] [Abstract][Full Text] [Related]
12. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.
Betthauser TJ; Bilgel M; Koscik RL; Jedynak BM; An Y; Kellett KA; Moghekar A; Jonaitis EM; Stone CK; Engelman CD; Asthana S; Christian BT; Wong DF; Albert M; Resnick SM; Johnson SC;
Brain; 2022 Nov; 145(11):4065-4079. PubMed ID: 35856240
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging.
Yan Q; Nho K; Del-Aguila JL; Wang X; Risacher SL; Fan KH; Snitz BE; Aizenstein HJ; Mathis CA; Lopez OL; Demirci FY; Feingold E; Klunk WE; Saykin AJ; ; Cruchaga C; Kamboh MI
Mol Psychiatry; 2021 Jan; 26(1):309-321. PubMed ID: 30361487
[TBL] [Abstract][Full Text] [Related]
14. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
[TBL] [Abstract][Full Text] [Related]
15. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
[TBL] [Abstract][Full Text] [Related]
16. Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
Josephs KA; Weigand SD; Whitwell JL
Neurology; 2022 May; 98(22):e2282-e2292. PubMed ID: 35314506
[TBL] [Abstract][Full Text] [Related]
17. Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease.
Rubinski A; Frerich S; Malik R; Franzmeier N; Ramirez A; Dichgans M; Ewers M;
Ann Neurol; 2023 Apr; 93(4):819-829. PubMed ID: 36571564
[TBL] [Abstract][Full Text] [Related]
18. APOE effects on regional tau in preclinical Alzheimer's disease.
Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
[TBL] [Abstract][Full Text] [Related]
19. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ;
J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
